Spiegel Online

Samstag, 24. August 2019


BUSINESS WIRE: Gilead Sciences' Chief Scientific Officer John McHutchison to Leave the Company

17.07.2019, 14:30 Uhr


FOSTER CITY, Calif. --(BUSINESS WIRE)-- 17.07.2019 --

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor.

Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company's expansion into oncology with the development of Gilead's first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company's Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.

"Over the past nine years, John's scientific contributions and leadership have played an instrumental role in shaping our research efforts and in improving care for millions of patients with life-threatening illnesses," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead. "Under his guidance, the company was able to rapidly advance our hepatitis C portfolio, enabling therapies to reach people in need at an unprecedented pace, and he has continued to build on that work by helping the company expand its therapeutic areas of focus. We are grateful to John for his many contributions and wish him the best."

"It has been a privilege to work alongside many exceptionally talented scientists," said Dr. McHutchison. "I am grateful for the opportunity to make a difference in the lives of people with serious illnesses and confident that Gilead will continue to advance important new medicines for generations of patients to come."


About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company's website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Sung Lee, Investors
(650) 524-7792

Amy Flood, Media
(650) 522-5643

Weitere Nachrichten

22.08. BUSINESS WIRE: Themis Bioscience gibt exklusive Lizenzvereinbarung und Forschungskollaboration mit MSD zur Entwicklung von Impfstoffkandidaten bekannt
22.08. IRW-PRESS: AG: Neuer 512% Hot Stock kündigt größtes Medical Mushroom IPO an - Massives Kaufsignal. Neuer 512% Medical Mushroom Hot Stock nach 50.000% mit Aurora Cannabis und 294.900% mit Canopy Growth. Das nächste große Ding nach dem Cannab
22.08. BUSINESS WIRE: c-LEcta: Erfolgreiches Produktgeschäft im ersten Halbjahr 2019
22.08. IRW-PRESS: AG: Neuer 614% Pot Hot Stock verpflichtet Cannabis Börsenstar - Massives Kaufsignal - 255 mal günstiger als Aurora Cannabis und 332 mal günstiger als Canopy Growth. Neuer 614% Cannabis und Blockchain Hot Stock Codebase Ventures -
22.08. IRW-PRESS: Roadman Investments Corp. : Roadman Investments erhöht Volumen der Privatplatzierung und stellt Unternehmensupdate bereit
22.08. IRW-PRESS: ParcelPal Technology Inc.: ParcelPal gibt Lieferabkommen mit Aphria Inc. bekannt
22.08. IRW-PRESS: Codebase Ventures Inc.: Codebase-Tochtergesellschaft Code Cannabis Investments ernennt Herrn Zach Stadnyk zum President und CEO
22.08. BUSINESS WIRE: MobileIron erneut als führendes Unternehmen im Magic Quadrant für Unified Endpoint Management Tools der Gartner Group eingeordnet
22.08. IRW-PRESS: Amex Exploration Inc. : Amex informiert über den Stand der Exploration in drei Goldzonen des Konzessionsgebiets Perron
22.08. IRW-PRESS: Converge Technology Solutions Corp.: Converge Technology Solutions meldet Finanzergebnisse für das zweite Quartal 2019